Try our beta test site
4 studies found for:    epacadostat melanoma
Show Display Options
Rank Status Study
1 Recruiting A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)
Condition: Melanoma
Interventions: Drug: pembrolizumab + epacadostat;   Drug: pembrolizumab + placebo
2 Active, not recruiting Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma
Conditions: Mucosal Melanoma;   Recurrent Melanoma;   Recurrent Uveal Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIA Uveal Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIB Uveal Melanoma;   Stage IIIC Skin Melanoma;   Stage IIIC Uveal Melanoma;   Stage IV Skin Melanoma;   Stage IV Uveal Melanoma
Interventions: Drug: Epacadostat;   Other: Laboratory Biomarker Analysis;   Biological: MELITAC 12.1 Peptide Vaccine
3 Recruiting A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
Conditions: Melanoma;   Carcinoma, Non-Small-Cell Lung;   Colorectal Neoplasms;   Carcinoma, Squamous Cell of Head and Neck;   Ovarian Neoplasms;   B Cell NHL Including DLBCL;   HL;   Glioblastoma
Intervention: Drug: Nivolumab + Epacadostat
4 Recruiting A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)
Conditions: Selected Advanced Solid Tumors;   Non-small Cell Lung Cancer;   Melanoma;   Head and Neck Cancer;   Gastric Cancer;   Gastroesophageal Cancer;   Urothelial Cancer;   Triple Negative Breast Cancer
Interventions: Drug: MEDI4736;   Drug: INCB024360

Study has passed its completion date and status has not been verified in more than two years.